Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00265109
Recruitment Status : Completed
First Posted : December 14, 2005
Results First Posted : November 16, 2010
Last Update Posted : August 29, 2019
Sponsor:
Collaborator:
UCB Pharma
Information provided by (Responsible Party):
Butler Hospital

Brief Summary:
The purpose of this study is to assess the usefulness of a medication (Levetiracetam) for people with body dysmorphic disorder.

Condition or disease Intervention/treatment Phase
Body Dysmorphic Disorder Drug: Levetiracetam Phase 4

Detailed Description:

Body dysmorphic disorder (BDD), a perceived defect in appearance (e.g., a "large" nose or facial "scarring"), is a relatively common disorder that causes marked distress and impairment in functioning. Recent data suggests that adults with BDD may respond to serotonin reuptake inhibitors (SRIs); however, response to SRIs is often only partial. About one third of patients do not respond to an SRI. Furthermore, patients may stop taking SRIs because of side effects (e.g., sexual side effects). For these reasons, additional monotherapy and SRI augmentation strategies are greatly needed.

Levetiracetam is primarily used as an antiseizure medication and has a wider safety margin than other antiepileptics. Preliminary scientific studies may suggest that it may be helpful for certain psychiatric symptoms and disorders. In the present study we propose to obtain pilot data on 1) levetiracetam monotherapy and 2) levetiracetam augmentation of SRIs in patients with BDD.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label Study of Levetiracetam in Body Dysmorphic Disorder
Study Start Date : December 2004
Actual Primary Completion Date : January 2008
Actual Study Completion Date : January 2008

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
open label
Open-label trial; all participants received levetiracetam
Drug: Levetiracetam
The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week. The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day. The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic. Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.




Primary Outcome Measures :
  1. Number of Responders on the Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS) [ Time Frame: Baseline to end week 12 ]
    The BDD-YBOCS, a reliable and valid 12-item semi-structured clinician-administered scale assessed BDD severity during the past week. 38 items are rated from 0 (no symptoms) to 4 (extreme symptoms); range=0-48. This scale assesses preoccupation with the perceived appearance defects, associated compulsive behaviors, insight, and avoidance. A ≥30% decrease in total score indicated response.


Secondary Outcome Measures :
  1. Percentage of Participants Who Improved on the Body Dysmorphic Disorder Clinical Global Impressions Scale - Clinician Rating for BDD Symptoms [ Time Frame: Last week of treatment (week 12) or last week of treatment for early dropouts ]
    The Clinical Global Improvement Scale (CGI) is a widely used 7-point scale that assesses global improvement or worsening of symptoms, with ratings ranging from "very much worse" (score of 7) to "very much improved" (score 1). Ratings of much improved (score of 2) or very much improved (score of 1) defined improvement in BDD.

  2. Percentage of Subjects Who Improved on the Clinical Global Improvement Scale (CGI) -- Clinician Rating of Global Improvement. [ Time Frame: Last week of treatment (week 12) ]
    The CGI is a widely used 7-point scale that assesses global improvement or worsening of symptoms, with ratings ranging from "very much worse" (score of 7) to "very much improved" (score 1). Ratings of much improved (score of 2) or very much improved (score of 1) defined global improvement.

  3. Percentage of Participants Who Improved on the Body Dysmorphic Disorder Clinical Global Impressions Scale - Patient Rating for BDD Symptoms [ Time Frame: Last week of treatment (week 12) or last week of treatment for early dropouts ]
    The Clinical Global Improvement Scale (CGI) is a widely used 7-point scale that assesses global improvement or worsening of symptoms, with ratings ranging from "very much worse" (score of 7) to "very much improved" (score 1). Ratings of much improved (score of 2) or very much improved (score of 1) defined improvement in BDD.

  4. Percentage of Subjects Who Improved on the Clinical Global Improvement Scale (CGI) -- Patient Rating of Global Improvement. [ Time Frame: Last week of treatment (week 12) ]
    The CGI is a widely used 7-point scale that assesses global improvement or worsening of symptoms, with ratings ranging from "very much worse" (score of 7) to "very much improved" (score 1). Ratings of much improved (score of 2) or very much improved (score of 1) defined global improvement.

  5. Scores on Brown Assessment of Beliefs Scale [ Time Frame: Pre- and post-treatment (week 12) ]
    The Brown Assessment of Beliefs Scale (BABS) is a 7-item semi-structured clinician-administered scale that assesses seven components of delusionality (insight) during the past week. Scores range from 0-24, with higher scores indicating greater delusionality. Beliefs are also categorized as delusional or nondelusional using an empirically derived cutpoint.

  6. Scores on Clinical Global Severity [ Time Frame: Pre- and post-treatment (week 12) ]
    The 7-point Clinical Global Severity Scale assessed current illness severity at study baseline (score of 1=normal, not at all ill, and score of 7=among the most extremely ill patients).

  7. Scores on Hamilton Depression Rating Scale [ Time Frame: Pre- and post-treatment (week 12) ]
    The 24-item Hamilton Rating Scale for Depression (HAM-D 24) is a widely used reliable and valid clinician-administered measure of current severity of depressive symptoms. Scores range from 0 to 76, with higher scores reflecting more severe depressive symptoms.

  8. Scores on Beck Anxiety Inventory [ Time Frame: Pre- and post-treatment (week 12) ]
    The Beck Anxiety Inventory (BAI) is a reliable, valid, and widely used 21-item self-report measure of anxiety during the past week which focuses on somatic symptoms.44 The BAI has been shown to be sensitive to change. Scores range from 0-63, with higher scores reflecting more severe symptoms.

  9. Scores on Social Phobia Inventory [ Time Frame: Pre- and post-treatment (week 12) ]
    The Social Phobia Inventory (SPIN) is a 17-item self-report questionnaire that assesses fear, avoidance, and physiological arousal associated with social anxiety during the past week. This scale is reliable, valid, and sensitive to change. Scores range from 0-68, with a score ≥19 distinguishing patients with social phobia from both healthy controls and psychiatric controls without social phobia.

  10. Scores on Global Assessment of Functioning [ Time Frame: Pre- and post-treatment (week 12) ]
    The Global Assessment of Functioning (GAF) is a global measure of symptom severity and psychological, social, and occupational functioning. Scores range from 0-100, with lower scores denoting more severe illness and/or poorer functioning

  11. Scores on Social and Occupational Functioning Scale (SOFAS) [ Time Frame: Pre- and post-treatment (week 12) ]
    The Social and Occupational Functioning Scale (SOFAS) is a global measure of psychological, social, and occupational functioning. Scores range from 0-100, with lower scores denoting more severe illness and/or poorer functioning

  12. Scores on The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) -- Short Form [ Time Frame: Pre- and post-treatment (week 12) ]
    The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), Short Form, is a 14-item reliable and valid measure that is sensitive to change. Transformed scores range from 0 from 100, with lower scores reflecting poorer quality of life.The Short Form transformed score is reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women age 18-65;
  • Current DSM-IV BDD or its delusional variant (delusional disorder, somatic type) for at least 3 months;
  • A minimum total score of 20 on the Yale-Brown Obsessive Compulsive Scale Modified for BDD (BDD-YBOCS) (19);
  • Suitable for treatment in an outpatient setting

Exclusion Criteria:

  • Unstable medical illness, including renal failure or dialysis;
  • Myocardial infarction within 6 months;
  • Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;
  • A need for prn benzodiazepines, another antiepileptic medication, or an anticipated change in the dose of any concomitant medications while receiving treatment with levetiracetam;
  • Clinically significant suicidality, including a suicide attempt within the past two months;
  • Lifetime history of DSM-IV dementia, schizophrenia, or any other DSM-IV psychotic disorder that is not attributable to BDD;
  • Current or recent (past 3 months) DSM-IV substance abuse or dependence;
  • Initiation of ongoing psychotherapy from a mental health professional within 3 months prior to study baseline;
  • Ongoing cognitive-behavioral therapy from a mental health professional;
  • Previous treatment with levetiracetam;
  • Treatment with investigational medication, depot neuroleptics, or ECT within the past 3 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00265109


Locations
Layout table for location information
United States, Rhode Island
Rhode Island Hospital Body Dysmorphic Disorder Program
Providence, Rhode Island, United States, 02903
Sponsors and Collaborators
Butler Hospital
UCB Pharma
Investigators
Layout table for investigator information
Principal Investigator: Katharine A Phillips, M.D. Rhode Island Hospital/ Brown University

Additional Information:
Layout table for additonal information
Responsible Party: Butler Hospital
ClinicalTrials.gov Identifier: NCT00265109     History of Changes
Other Study ID Numbers: 0410-001
First Posted: December 14, 2005    Key Record Dates
Results First Posted: November 16, 2010
Last Update Posted: August 29, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Butler Hospital:
body dysmorphic disorder
levetiracetam
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Body Dysmorphic Disorders
Pathologic Processes
Somatoform Disorders
Mental Disorders
Levetiracetam
Anticonvulsants
Nootropic Agents